Back to Search
Start Over
Combined analysis of CSF βA42 peptide and tau protein and serum antibodies to glycosaminoglycans in Alzheimer's disease: preliminary data
- Source :
- Journal of Neural Transmission. 109:393-398
- Publication Year :
- 2002
- Publisher :
- Springer Science and Business Media LLC, 2002.
-
Abstract
- Neuropathological hallmarks of Alzheimer's disease (AD) are amyloid plaques and neurofibrillary tangles, containing betaA(42) peptide and tau protein, respectively. Amyloid plaques contain also glycosaminoglycans (GAGs). Whereas cerebrospinal fluid (CSF) levels of betaA(42) peptide and tau protein have been demonstrated as potential markers of Alzheimer's disease (AD), no data are available for GAGs. We determined (Elisa) tau and betaA(42) CSF levels, as well as serum antibodies to GAGs in 9 AD patients, and the values were analyzed in relation to age and severity of the disease. Beta-A42 and tau CSF levels were significantly reduced and increased, respectively, in AD patients when compared to controls, but they did not correlate with the severity of the disease. Despite their role in amyloidogenesis, we did not find evidence for the use of GAGs as diagnostic marker of AD.
- Subjects :
- Pathology
medicine.medical_specialty
Tau protein
Plaque, Amyloid
tau Proteins
Peptide
Antibodies
Central nervous system disease
Glycosaminoglycan
Cerebrospinal fluid
Degenerative disease
Alzheimer Disease
medicine
Humans
Biological Psychiatry
Aged
Glycosaminoglycans
chemistry.chemical_classification
Amyloid beta-Peptides
biology
Chemistry
Brain
Neurofibrillary Tangles
Middle Aged
medicine.disease
Peptide Fragments
Psychiatry and Mental health
Neurology
Disease Progression
biology.protein
Neurology (clinical)
Alzheimer's disease
Antibody
Subjects
Details
- ISSN :
- 14351463 and 03009564
- Volume :
- 109
- Database :
- OpenAIRE
- Journal :
- Journal of Neural Transmission
- Accession number :
- edsair.doi.dedup.....33938c9faac69b98028c35babf849d62